With fresh com­pa­ny build­ing lessons from Abl­ynx, Ed­win Moses is ready to try it again as chair of neoanti­gen biotech Achilles

Af­ter of­fi­cial­ly pass­ing off Abl­ynx to Sanofi in Ju­ly, Ed­win Moses took Au­gust off — the longest break the biotech CEO has had in about 20 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.